- Home
- EMX vs BNTC Comparison
EMX vs BNTC Comparison
Compare EMX & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- BNTC
- Stock Information
- Founded
- EMX N/A
- BNTC 1995
- Country
- EMX Canada
- BNTC United States
- Employees
- EMX N/A
- BNTC N/A
- Industry
- EMX
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- BNTC Health Care
- Exchange
- EMX Nasdaq
- BNTC Nasdaq
- Market Cap
- EMX 338.0M
- BNTC 335.5M
- IPO Year
- EMX N/A
- BNTC N/A
- Fundamental
- Price
- EMX $3.65
- BNTC $13.24
- Analyst Decision
- EMX Strong Buy
- BNTC Strong Buy
- Analyst Count
- EMX 2
- BNTC 5
- Target Price
- EMX $5.38
- BNTC $26.00
- AVG Volume (30 Days)
- EMX 431.3K
- BNTC 39.5K
- Earning Date
- EMX 08-11-2025
- BNTC 09-25-2025
- Dividend Yield
- EMX N/A
- BNTC N/A
- EPS Growth
- EMX N/A
- BNTC N/A
- EPS
- EMX 0.04
- BNTC N/A
- Revenue
- EMX $29,864,000.00
- BNTC N/A
- Revenue This Year
- EMX $11.08
- BNTC N/A
- Revenue Next Year
- EMX $3.72
- BNTC N/A
- P/E Ratio
- EMX $79.37
- BNTC N/A
- Revenue Growth
- EMX N/A
- BNTC N/A
- 52 Week Low
- EMX $1.59
- BNTC $8.06
- 52 Week High
- EMX $3.66
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- EMX 74.62
- BNTC 59.72
- Support Level
- EMX $3.04
- BNTC $12.57
- Resistance Level
- EMX $3.37
- BNTC $13.33
- Average True Range (ATR)
- EMX 0.12
- BNTC 0.60
- MACD
- EMX 0.03
- BNTC 0.10
- Stochastic Oscillator
- EMX 97.58
- BNTC 95.59
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.